Overall, these findings suggest that GPER-mediated signalling within the TME may contribute to the reduced effectiveness of CDK4/6 inhibitors, underscoring the need to consider stromal-tumour interactions to overcome therapeutic resistance. This evidence concerns the gene CDK4 and neoplasm.